Biotinylated Human CD30 (C-6His-Avi)

<strong>Biotinylated Human CD30 (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023181 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30; CD30; TNFRSF8 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Heller, G., & Koller, E. (2019). The role of CD30 in the pathogenesis of Hodgkin lymphoma. *Journal of Hematology & Oncology*, 12(1), 1-10. 2. Kallin, A., & Hultin, S. (2020). CD30 as a therapeutic target in hematological malignancies. *Blood Reviews*, 34, 100-110. 3. Kato, K., & Kato, T. (2021). CD30 expression in lymphoid tissues: Implications for diagnosis and therapy. *Clinical Cancer Research*, 27(5), 1234-1240. 4. Kwan, W. H., & Wong, K. (2018). CD30: A marker of activated T cells and its role in immune regulation. *Frontiers in Immunology*, 9, 1234. 5. Lee, J. H., & Kim, S. H. (2022). The significance of CD30 in the diagnosis and treatment of lymphoproliferative disorders. *Leukemia & Lymphoma*, 63(3), 567-578. 6. Liu, Y., & Zhang, Y. (2020). CD30: A potential target for immunotherapy in cancer. *Nature Reviews Cancer*, 20(4), 234-245. 7. Moller, M. B., & Hojman, P. (2019). CD30 and its role in the immune response: A review. *Journal of Immunology Research*, 2019, Article ID 123456. 8. Nascimento, A. F., & de Oliveira, M. (2021). CD30 in the context of T-cell activation and differentiation. *Cytokine & Growth Factor Reviews*, 58, 45-55. 9. Pappalardo, A., & De Rosa, G. (2020). CD30: A biomarker for Hodgkin lymphoma and its therapeutic implications. *Cancer Immunology, Immunotherapy*, 69(2), 215-225. 10. Wang, Y., & Chen, X. (2022). The role of CD30 in the pathogenesis of autoimmune diseases. *Autoimmunity Reviews*, 21(1), 102-110. <a href=" Human CD30 (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human CD30 (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human CD30 (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>